Barclays’s Axsome Therapeutics AXSM Stock Holding History

Barclays’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-27,500	Closed	-$2.19M	–	4868
2024 Q1	$2.19M	Sell	27,500 -24,500	-47%	-$2.06M	﹤0.01%	2480
2023 Q4	$4.14M	Buy	+52,000	New	+$3.48M	﹤0.01%	2274
2020 Q2	–	Sell	-201,500	Closed	-$11.9M	–	5564
2020 Q1	$11.9M	Buy	201,500 +136,600	+210%	+$11.1M	0.01%	902
2019 Q4	$6.71M	Buy	64,900 +45,000	+226%	+$1.82M	﹤0.01%	1733
2019 Q3	$403K	Sell	19,900 -39,400	-66%	-$1.01M	﹤0.01%	4415
2019 Q2	$1.53M	Sell	59,300 -37,800	-39%	-$758K	﹤0.01%	3220
2019 Q1	$1.38M	Buy	+97,100	New	+$902K	﹤0.01%	3035

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's AXSM Position: Q1 2026 in Review

Barclays reduced its Axsome Therapeutics (AXSM) stake by 55% in Q1 2026, selling an estimated $7.36M and leaving 34,261 shares worth $5.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1726.

Barclays first reported a position in AXSM in Q3 2016 and has held it in 32 quarters since. The position peaked at $17.6M in Q1 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Barclays held 34,261 shares of Axsome Therapeutics worth $5.79M as of Q1 2026.
Barclays sold 42,592 Axsome Therapeutics shares in Q1 2026, an estimated $7.36M.
Axsome Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1726 holding.
Barclays first reported a position in Axsome Therapeutics in Q3 2016 and has held it in 32 quarters since.
Barclays's Axsome Therapeutics position peaked at $17.6M in Q1 2024.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.